Recurrent Vulvovaginal Candidiasis (RVVC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Recurrent Vulvovaginal Candidiasis (RVVC) Market Outlook

Thelansis’s “Recurrent Vulvovaginal Candidiasis (RVVC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Vulvovaginal Candidiasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Recurrent Vulvovaginal Candidiasis (RVVC) Overview

Recurrent vulvovaginal candidiasis (RVVC) is characterized by experiencing four or more confirmed episodes of vulvovaginal candidiasis within a year, and it presents a significant challenge in effectively managing this infection. It typically results from a relapse caused by the same persistent strains of C. albicans rather than a new infection caused by different strains. This condition is more likely to develop in environments with elevated estrogen levels and often affects pregnant women. Recurrent thrush is relatively uncommon, affecting approximately 5-8% of women of reproductive age. Yet, it can profoundly impact women's quality of life, leading to symptoms like vulvar itching, soreness, painful urination, painful intercourse, and the characteristic "cottage cheese-like" vaginal discharge. Primary RVVC is considered idiopathic, as its underlying predisposing factors are unknown. It occurs in otherwise healthy, immunocompetent women, most of whom do not have identifiable triggers or causative factors. On the other hand, when frequent episodes of acute VVC are linked to predisposing factors such as hormone replacement therapy or diabetes mellitus, it is referred to as secondary RVVC. In June 2021, the FDA (Food and Drug Administration) approved a novel oral glucan synthase inhibitor called ibrexafungerp for treating recurrent vulvovaginal candidiasis.

• VVC is the most common candidal infection in humans, affecting around 75% of women at least once during their lifetime. Furthermore, recurrent VVC impacts nearly 8% of women worldwide.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: